APSR2026-525

 
Late-Breaking
Submitted
Poster Presentation
 
AP16-012
P128
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1198377-46904-APSR-525_439664.pdf
Format: PDF Only
15. Pulmonary Circulation
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Sugeesha Wickramasinghe * Royal Preston Hospital Respiratory Medicine Preston United Kingdom
Sean Connell - Royal Preston Hospital Respiratory Medicine Preston United Kingdom
Sarah Macrae - Royal Preston Hospital Respiratory Medicine Preston United Kingdom
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Sugeesha
Wickramasinghe
sugeesha@gmail.com
+447459038508
31-40
Sri Lanka
Case Report
low BMI, DOAC, Saddle embolism
Maximum 25 words
Abstract Content
 
 
 
 
Pulmonary embolism (PE) is a potentially life-threatening condition requiring prompt anticoagulation. Direct oral anticoagulants (DOACs), including Apixaban, are widely recommended; however, evidence supporting their use in patients with extremely low body mass index (BMI) is limited. This creates clinical uncertainty due to concerns regarding altered pharmacokinetics and increased bleeding risk in this population.
An 88-year-old female presented with acute onset dyspnoea. Two weeks prior, she had been hospitalised following a fall resulting in bilateral rib fractures, clavicular fracture, and thoracic vertebral fractures. On admission, she was hypoxic and denied chest pain or haemoptysis. Computed tomography pulmonary angiography revealed a saddle pulmonary embolism with bilateral emboli. Serum troponin was significantly elevated at 401 ng/L (reference 5–14 ng/L). Transthoracic echocardiography demonstrated right ventricular dilatation with impaired systolic function, consistent with intermediate–high risk PE. She was commenced on weight-adjusted therapeutic Enoxaparin for five days, followed by Apixaban 5 mg twice daily. After six months, the dose was reduced to 2.5 mg twice daily for extended lifelong anticoagulation. Her medical history included aortic stenosis, triple-vessel coronary artery disease, and peripheral vascular disease, for which she was taking Clopidogrel. Her body weight was 33 kg (BMI 14 kg/m²). Following multidisciplinary discussion, standard-dose Apixaban was continued despite limited evidence in this population. Clopidogrel was discontinued due to increased bleeding risk. Repeat echocardiography at three months showed resolution of right ventricular dysfunction and pulmonary hypertension. The patient remained clinically stable without bleeding complications.
This case highlights the challenges of anticoagulation in patients with extremely low BMI and high-risk PE features. DOAC therapy may be a safe and effective option in this population when guided by careful risk–benefit assessment and close monitoring. Further studies are required to establish optimal dosing strategies in low BMI patients.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
saddle PE, Low BMI, DOAC
maximum 3 keywords and no abbreviations, separated by commas
 
294